Hydrogen Capsules Help Immune System in Lupus Heart Disease Patient

TL;DR

In an SLE patient with pulmonary hypertension, hydrogen capsule therapy led to clinical improvement and revealed a biphasic immune response—initial suppression of T cell and B cell activation, followed by regulatory rebound after therapy cessation.

Key Finding

In one SLE patient with pulmonary arterial hypertension, hydrogen capsule therapy appeared to suppress certain immune activation markers during treatment, followed by a rebound of regulatory immune cells after therapy stopped.

Summary

This case report describes one 45-year-old woman with systemic lupus erythematosus (SLE, an autoimmune disease) who also had pulmonary arterial hypertension (PAH, high blood pressure in the lungs). She received hydrogen capsules as an additional treatment, and researchers tracked changes in her immune cells over time. They found that certain immune cells decreased while she was taking hydrogen, then increased again after she stopped—suggesting hydrogen may have a two-phase effect on the immune system.

Practical Takeaway

This is a single case report, not a controlled study, so it provides only preliminary evidence that hydrogen capsules may affect immune function in SLE-related lung disease. Much larger and more rigorous studies would be needed to determine whether hydrogen actually helps patients with this condition or what the optimal dosing and duration should be. Anyone with SLE or PAH considering hydrogen therapy should discuss it with their doctor first.

Abstract (excerpt)

Background/aim: Pulmonary arterial hypertension (PAH) is a severe complication of systemic lupus erythematosus (SLE), marked by vascular remodeling, immune dysregulation, and progressive right heart failure. Molecular hydrogen therapy, a selective antioxidant and anti-inflammatory agent, has…

Read the full abstract via DOI